Kymera Therapeutics
(NASDAQ) KYMR
Kymera Therapeutics Financials at a Glance
Market Cap
$9.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$51.47M
Net Income (TTM)
-$315.05M
EPS (TTM)
-$3.57
P/E Ratio
-33.39
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Price
$119.40
Volume
736
Open
$115.26
Price
$119.40
Volume
736
Open
$115.26
Previous Close
$119.24
Daily Range
$115.02 - $120.90
52-Week Range
$36.65 - $130.05
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Price
$119.40
Volume
736
Open
$115.26
Previous Close
$119.24
Daily Range
$115.02 - $120.90
52-Week Range
$36.65 - $130.05
Estimated Earnings Date
Aug 10, 2026
KYMR News
KYMR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Kymera Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
238
CEO
Nello Mainolfi, PhD
Website
www.kymeratx.comHeadquarters
Watertown, MA 02472, US
KYMR Financials
Key Financial Metrics (TTM)
Gross Margin
100.00%
Operating Margin
-697.81%
Net Income Margin
-612.17%
Return on Equity
-25.02%
Return on Capital
-21.02%
Return on Assets
-18.88%
Earnings Yield
-2.99%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$9.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
82.26M
Volume
736
Avg. Volume
775.11K
Financials (TTM)
Gross Profit
$51.47M
Operating Income
-$359.13M
EBITDA
-$306.05M
Operating Cash Flow
-$242.58M
Capital Expenditure
-$1.42M
Free Cash Flow
-$244.00M
Cash & ST Invst.
$650.93M
Total Debt
$80.47M
Kymera Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$34.37M
+55.5%
Gross Profit
$34.37M
+55.5%
Gross Margin
100.00%
N/A
Market Cap
$9.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$38.77M
N/A
Employees
253
N/A
Net Income
-$69.23M
-5.6%
EBITDA
-$67.15M
-5.8%
Quarterly Fundamentals
Total Cash
$650.93M
+40.5%
Total Debt
$80.47M
-6.8%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$66.74M
-8.7%
Short Term Debt
$13.73M
+3.7%
Return on Assets
-18.88%
N/A
Return on Invested Capital
-22.36%
N/A
Free Cash Flow
-$89.27M
-12.1%
Operating Cash Flow
-$88.84M
-12.2%